Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Centrus Contract Win

3 Dec 2012 07:00

RNS Number : 5017S
Instem plc
03 December 2012
 



03 December 2012

Embargoed for 07:00

 

Instem plc

("Instem", the "Company" or the "Group")

 

Centrus Contract Win with Top 10 Pharma

 

Leading Global Biopharmaceutical Company Purchases Instem's Centrus Software to Convert, Create and Share Research Study Data

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces today that it has signed a contract with one of the world's largest biopharmaceutical organisations. The customer has purchased multiple modules of the Centrus software suite supporting the Standard for Exchange of Nonclinical Data (SEND). This six-figure US Dollar order is the most comprehensive suite of Centrus modules purchased to date.

 

Instem's software will be used to reduce time and effort by translating study data to controlled terminology and automatically checking against SEND guidelines to ensure compliance. Additionally it includes the capability for the management, secure storage and sharing of SEND datasets with external partners.

 

The SEND standard, named by the US Food & Drug Administration ("FDA") as the preferred standard for electronic study submissions, is expected to revolutionise the process for both pharmaceutical companies and regulators. Currently, FDA reviewers receive paper or electronic paper submissions, which require time-consuming manual data input. The SEND format enables electronic submissions of nonclinical data, thereby improving efficiency as well as data quality, accessibility and predictability.

 

Instem has been an industry leader in SEND since 2004, and has been an active contributing member to several committees dedicated to advancing and promoting the standard alongside the US Food & Drug Administration (FDA). The Group's leading position in this developing area was underlined in February 2012, when Instem was recognised for its outstanding contributions to SEND at the Interchange North America event organised by CDISC, the Clinical Data Interchange Standards Consortium.

 

This order is one of a number of contracts currently under negotiation which have a possibility of closure before the year end. Some of these are required to meet revenue and profit expectations for the year. Instem expects to update on trading prior to closing the financial year ending 31 December 2012.

 

Phil Reason, CEO of Instem plc, commented: "I am delighted to announce this contract with one of the largest international biopharmaceutical companies for our innovative Centrus suite. This customer is at the forefront of developing SEND for regulatory submission as well as facilitating the aggregation of internally and externally generated study data to improve early development productivity. Given our central position in the development of the SEND standard and our established global Provantis customer base, we believe future opportunities for Centrus to be significant."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 3205 7500

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBMBRTMBMJBPT
Date   Source Headline
18th May 20071:09 pmRNSRule 8.3- Intnl Nuclear Sol.
17th May 20075:02 pmRNSRule 8.3- Int Nuclear Sol
17th May 20073:25 pmBUSRule 8.3 - International Nuclear Solutions
16th May 20079:13 amRNSNotification of shares
14th May 200710:40 amRNSEGM ADJOURNMENT
11th May 200711:48 amRNSHolding(s) in Company
11th May 20079:42 amRNSHolding(s) in Company
10th May 20073:04 pmBUSRule 8.3 - International Nuclear Solution
10th May 20071:44 pmRNSRule 8.3-Int'l Nuclear Sol
1st May 200711:44 amRNSHolding(s) in Company
1st May 200710:00 amRNSRule 8.3- Intnl Nuclear Sols
30th Apr 20074:26 pmRNSHolding(s) in Company
26th Apr 20073:29 pmBUSRule 8.3 - International Nuclear Solutions
26th Apr 20073:07 pmRNSRule 8.3-Intl Nuclear Sol
26th Apr 20072:28 pmRNSRule 8.3- Intl Molybdenum plc
25th Apr 20073:17 pmBUSRule 8.3 - International Nuclear Solutions
25th Apr 200712:41 pmRNSRule 8.3- Int'l Nuclear Sol
23rd Apr 20071:34 pmRNSRule 8.3-Int. Nuclear
20th Apr 20074:30 pmRNSPosting of Scheme Document
18th Apr 20073:32 pmBUSRule 8.3 - International Nuclear Solutions
18th Apr 200710:09 amRNSRule 8.3- Intnl Nuclear Sol.
12th Apr 20073:05 pmBUSRule 8.3 - International Nuclear Solutions
5th Apr 20075:02 pmBUSRule 8.3 - International Nuclear Solution
5th Apr 200711:39 amRNSRule 8.3- Intnl Nuclear Sol.
5th Apr 200711:00 amRNSRule 8.3- Intnl Nuclear Sol
4th Apr 20074:21 pmRNSRule 8.3- Int Nuclear Sol
4th Apr 20073:30 pmBUSRule 8.3 - International Nuclear Solutions
4th Apr 200711:47 amRNSRule 8.3- Intnl Nuclear Sol.
4th Apr 20077:02 amRNSRecommended Cash Offer
4th Apr 20077:02 amRNSScheme of arrangement
3rd Apr 20075:29 pmRNSCorrection to Prelims
30th Mar 20073:13 pmBUSRule 8.3 - International Nuclear Solutions
29th Mar 20073:21 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
28th Mar 20073:27 pmRNSRule 8.3-Int Nuclear Sol
27th Mar 20077:02 amRNSFinal Results
26th Mar 200711:37 amRNSRule 8.3- Intnl Nuclear Sol.
23rd Mar 20073:26 pmBUSRule 8.3 - International Nuclear Solutions
19th Mar 200711:06 amRNSRule 8.3- Intnl Nuclear Sol.
8th Mar 200711:59 amRNSRule 8.3- Intnl Nuclear Sol.
20th Feb 20072:34 pmBUSRule 8.3 - Internationa Nuclear Solutions
16th Feb 200710:50 amRNSRule 8.3- Intnl Nuclear Sol.
12th Feb 200712:06 pmRNSRule 8.3- Intnl Nuclear Sol.
7th Feb 20073:18 pmBUSRule 8.3 - International Nuclear Solutions
1st Feb 200710:40 amRNSRule 8.3- Intnl Nuclear Sol.
30th Jan 200711:01 amRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20072:39 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 20071:51 pmRNSRule 8.3- Intnl Nuclear Sol.
29th Jan 200711:00 amRNSRule 8.3- Intnl Nuclear
26th Jan 20075:45 pmRNSShare Interest
26th Jan 20073:20 pmRNSRule 8.1- Int Nuclear Sols

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.